|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4900 CAD | -2.00% |
|
-5.77% | +7.69% |
| Jun. 03 | PharmaCorp Rx Initiated at Outperform, $0.70 Price Target at Raymond James | MT |
| Jun. 01 | Earnings Flash (PCRX.V) PharmaCorp Reports Q1 Revenue $7.2M, Up 79.4% YoY | MT |
Company Valuation: PharmaCorp Rx Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 63.34 | 75.95 | 87.04 | - | - |
| Change | - | 19.91% | 14.6% | - | - |
| Enterprise Value (EV) 1 | 63.34 | 53.55 | 95.64 | 89.94 | 101.3 |
| Change | - | -15.46% | 78.61% | -5.96% | 12.62% |
| P/E | -54x | -45.5x | - | - | - |
| PBR | - | - | 1.67x | 1.56x | - |
| PEG | - | - | - | - | - |
| Capitalization / Revenue | - | 3.64x | 1.8x | 0.9x | 1.01x |
| EV / Revenue | - | 2.56x | 1.97x | 0.93x | 1.18x |
| EV / EBITDA | - | 15.2x | 20.3x | 8.14x | 8.96x |
| EV / EBIT | - | - | 43.1x | 12.7x | 12.1x |
| EV / FCF | - | 27.9x | -41.1x | 15.2x | 14.3x |
| FCF Yield | - | 3.58% | -2.43% | 6.6% | 6.98% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -0.01 | -0.01 | - | - | - |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | - | 20.89 | 48.48 | 96.23 | 86.17 |
| EBITDA 1 | - | 3.528 | 4.707 | 11.06 | 11.31 |
| EBIT 1 | - | - | 2.217 | 7.074 | 8.385 |
| Net income | -1.013 | -1.481 | - | - | - |
| Net Debt 1 | - | -22.4 | 8.6 | 2.9 | 14.25 |
| Reference price 2 | 0.5400 | 0.4550 | 0.5000 | 0.5000 | 0.5000 |
| Nbr of stocks (in thousands) | 117,296 | 166,927 | 174,082 | - | - |
| Announcement Date | 4/22/25 | 4/29/26 | - | - | - |
1CAD in Million2CAD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 1.97x | 20.32x | - | 61.29M | |
| 15.48x | 0.59x | 9.28x | -.--% | 13.38B | |
| 19.09x | 0.91x | 14.13x | -.--% | 6.35B | |
| 15.25x | 0.68x | 7.03x | 2.45% | 5.62B | |
| 15.97x | 0.97x | 7.25x | 4.04% | 3.31B | |
| 14.51x | 1.23x | 7.47x | 5.7% | 3.24B | |
| 12.01x | 0.76x | 5.45x | 3.58% | 3.4B | |
| 41.1x | - | - | - | 2.67B | |
| 12.39x | 0.5x | 3.95x | 5.58% | 2.71B | |
| Average | 18.23x | 0.95x | 9.36x | 3.05% | 4.52B | |
| Weighted average by Cap. | 17.16x | 0.75x | 8.72x | 1.92% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PCRX Stock
- Valuation PharmaCorp Rx Inc.
Select your edition
All financial news and data tailored to specific country editions
